Quickstart Highlights

CJC-1295 DAC is a long-acting synthetic analog of growth hormone-releasing hormone (GHRH). The DAC (Drug Affinity Complex) modification binds reversibly to albumin, extending the peptide’s half-life to approximately 6–8 days^[1]. By stimulating pituitary GHRH receptors, CJC-1295 DAC increases GH secretion and circulating IGF-1 in a dose-dependent manner^[2]. This educational protocol presents a twice-weekly subcutaneous approach using a practical dilution for clear insulin-syringe measurements.

• Reconstitute: Add 2.0 mL bacteriostatic water → 2.5 mg/mL (2500 mcg/mL) concentration.
• Typical dose range: 300–1000 mcg per injection, twice weekly (gradual titration).
• Easy measuring: At 2.5 mg/mL, 1 unit = 0.01 mL = 25 mcg on a U-100 insulin syringe.
• Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

Protocol Overview

Concise summary of the twice-weekly regimen.

• Goal: Support sustained GH and IGF-1 elevation for research into GH-axis effects^[1].
• Schedule: Twice-weekly subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
• Dose Range: 300–1000 mcg per injection with gradual titration.
• Reconstitution: 2.0 mL per 5 mg vial (2.5 mg/mL) for accurate unit measurements.
• Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Dosing Protocol

Suggested twice-weekly titration approach.

• Start: 300 mcg per injection twice weekly; increase by ~250 mcg every 2 weeks as tolerated.
• Target: 750–1000 mcg per injection by Weeks 5–12.
• Frequency: Twice per week (subcutaneous), spaced 3–4 days apart.
• Cycle Length: 8–12 weeks; optional extension to 16 weeks.
• Timing: Consistent timing (e.g., evenings); rotate injection sites.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); stable for 2–4 weeks; avoid freeze–thaw.
• Allow vials to reach room temperature before opening to reduce condensation uptake.

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
• Inject slowly; wait a few seconds before withdrawing the needle.
• Document each dose, injection site, and timing to maintain consistency.
• The DAC modification provides sustained release; maintain consistent twice-weekly scheduling.
• The 5 mg vial provides more doses per vial, reducing reconstitution frequency.

How This Works

CJC-1295 DAC mimics endogenous GHRH, binding to GHRH receptors on pituitary somatotrophs to drive GH release^[2]. The DAC modification (albumin-binding moiety) keeps the GHRH analog circulating for days rather than minutes, extending the half-life to approximately 6–8 days^[1]. The resulting GH surge stimulates IGF-1 production (primarily in the liver); IGF-1 then mediates many growth and metabolic effects through JAK/STAT signaling pathways^[4]. Notably, pulsatile GH secretion persists even during continuous CJC-1295 stimulation, preserving physiological release patterns^[2].

Potential Benefits & Side Effects

Observations from preclinical and clinical literature.

• Supports sustained elevation of GH and IGF-1 in a dose-dependent manner^[1].
• May promote increased lean body mass, reduced fat mass, and improved body composition consistent with GH/IGF-1 axis activation^[4][9].
• Enhanced protein synthesis and recovery potential through anabolic signaling^[4].
• Generally well tolerated in clinical studies; occasional mild injection-site reactions (redness, swelling) may occur^[1].
• Some individuals report transient flushing, headache, or water retention during initial titration.

Lifestyle Factors

Complementary strategies for best outcomes.

• Pair with a balanced, protein-forward diet tailored to energy and recovery needs.
• Combine resistance training and aerobic activity to reinforce GH-mediated adaptations.
• Prioritize quality sleep (7–9 hours) as endogenous GH release peaks during deep sleep^[4].
• Manage stress to support hormonal balance and adherence.

Injection Technique

General subcutaneous guidance from clinical best-practice resources^[5][6].

• Clean the vial stopper and skin with alcohol; allow to dry.
• Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue^[5][8].
• Do not aspirate for subcutaneous injections; inject slowly and steadily^[5].
• Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy^[6][7].
• Do not rub or massage the injection site after administration^[8].

Recommended Source

Note: Product availability and specifications subject to change. Verify current product details on supplier website.

Shop at Amino Labs

References